Teverelix

Drug Profile

Teverelix

Alternative Names: EP-24332; Teverelix ER; Teverelix IR; Teverelix LA; Teverelix SR

Latest Information Update: 05 May 2011

Price : $50

At a glance

  • Originator Zentaris
  • Developer Ardana plc
  • Class Antihormones
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Benign prostatic hyperplasia; Endometriosis; Prostate cancer
  • Discontinued Female infertility; Male contraception; Uterine leiomyoma

Most Recent Events

  • 05 May 2011 No development reported - Phase-II for Prostate cancer in United Kingdom (SC)
  • 05 May 2011 No development reported - Phase-II for Prostate cancer in United Kingdom (IM)
  • 05 May 2011 No development reported - Phase-I for Endometriosis in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top